For individuals living with sickle cell disease (SCD), the transition from pediatric to adult care can be one of the most ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...

A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Iron overload is prevalent among adults with sickle cell disease (SCD), according to a study presented at the annual meeting ...

Key HighlightsMotixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies90% (9 of 10) of patients ...

Late effects are rare for patients with sickle cell disease (SCD) undergoing allogeneic hematopoietic cell transplantation ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications ...

Topline results from the RISE UP phase 3 trial demonstrated that mitapivat significantly improved hemoglobin response in patients with sickle cell disease.

Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of long-term hematopoietic stem cells (LT-HSCs) with at least one ...